Key result
Adding olprinone to lipoPGE1 lowers pressure gradient ~56% in an extremely low-birth-weight infant with aortic coarctation.
Why the study?
Does the addition of a PDE3 inhibitor to lipoPGE1 improve the pressure gradient and left ventricular function in an extremely low-birth-weight infant with simple aortic coarctation and left heart failure?
Population
1 extremely low-birth-weight female infant with simple aortic coarctation after ductus arteriosus ligation
Comparison
Phosphodiesterase-3 inhibitor olprinone combined with lipoPGE1
Design
Case report
Authors
Loading...
May support adjunctive PDE3 inhibition in low-birth-weight coarctation; leaves open confirmation in prospective trials.
Case Report (n=1)
Does the addition of a PDE3 inhibitor to lipoPGE1 improve the pressure gradient and left ventricular function in an extremely low-birth-weight infant with simple aortic coarctation and left heart failure?
The addition of a PDE3 inhibitor to lipoPGE1 may improve the pressure gradient and left ventricular function in extremely low-birth-weight infants with simple aortic coarctation.
Hawaka et al. (2025) conducted a case report in Simple aortic coarctation and left heart failure (n=1). Phosphodiesterase-3 (PDE3) inhibitor (olprinone) combined with liposomal prostaglandin E1 (lipoPGE1) vs. lipoPGE1 alone (prior to combination) was evaluated on Pressure gradient between upper and lower limbs. In an extremely low-birth-weight infant with simple aortic coarctation, adding the PDE3 inhibitor olprinone to lipoPGE1 reduced the upper-to-lower limb pressure gradient from 55 mmHg to 24 mmHg.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: